MRSH:NYSEMarsh Analysis

Marsh & McLennan (MRSH) trades around $162.33, sitting above the 20‑day SMA ($164.36) but below the 50‑day ($169.90) and 200‑day ($184.23) averages, signaling a bearish price trend. The RSI of 42.7 and a decreasing volume trend reinforce the near‑term weakness, although the MACD histogram (+0.27) and a bullish MACD crossover suggest a potential short‑term bounce. Fundamentally, the company posts solid revenue growth (7.6% YoY), a high ROE (27.6%), and a sustainable dividend yield of 2.22% with a payout ratio under 45%. However, its trailing PE of 20.3 sits well above the industry average of 16.7, and the DCF‑derived fair value of $142.3 is markedly lower than the current price, indicating the stock is overvalued at present. Analyst sentiment remains positive, with a consensus “Buy” rating, a Citi upgrade to Buy, and a median 12‑month price target near $200, implying roughly 23% upside despite the valuation gap.
Given the mix of technical pressure, elevated valuation, but strong fundamentals and dividend stability, the recommendation leans toward a cautious stance: hold in the short term while monitoring for a technical rebound, and consider buying on pull‑backs for medium‑ to long‑term investors seeking dividend income and growth exposure.